Radiosynovectomy's clinical applications and cost effectiveness: a review.
It is apparent that from the work of the authors and many others, including the work of Rivard, Sledge, Zuckerman, among others, that radiosynovectomy has an important role to play in providing effective treatment of affected joints associated with rheumatoid arthritis and other forms of arthritis as well as the hemophiliac joint. The treatment offers relief from the effects of recurrent joint effusion with an approximately 60% to 66% favorable response and from recurrent hemarthrosis in the hemophiliac joint with an approximately 75% to 80% favorable response. The impact of providing radiosynovectomy as an alternative to surgical synovectomy is seen, where postoperative side effects such as joint stiffness are avoided, improved quality of life is repeatedly documented, and the cost savings in health care dollars, particularly evident in the hemophiliac joint in this relatively small population, are potentially enormous. With almost two million people in the United States suffering from rheumatoid arthritis, the potential savings in health care dollars is also enormous. As with any use of in vivo radiopharmaceuticals, the potential for radiation-induced damage exists. However, with a 25 plus year record of use, more optimally configured radiopharmaceuticals, and the addition of maneuvers to minimize potential joint leakage, the risk of radiation induced damage appears to be minimal. It appears as though radiosynovectomy is an effective as well as cost-effective alternative to surgical synovectomy and is becoming the procedure of choice particularly in the hemophiliac patient with recurrent hemarthrosis and synovitis who has failed medical therapy. It is also the procedure of choice in patients for whom surgery is contraindicated because of the presence of clotting factor inhibitors.
Siegel
M E
ME
Division of Nuclear Medicine, University of Southern California School of Medicine, Los Angeles, USA.
Siegel
H J
HJ
Luck
J V
JV
D001172:Arthritis, Rheumatoid / Q000532:radiotherapy*; D003362:Cost-Benefit Analysis; D005260:Female; D006395:Hemarthrosis / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013583:Synovial Membrane / Q000528:radiation effects*; D013585:Synovitis / Q000532:radiotherapy*
D019275:Radiopharmaceuticals